UTHR
United Therapeutics Corporation · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +6.7% ·
share flow -3.6% ·
net new positions +6.2%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 86.02K | $43.82M | n/a | −2 |
| Q2 2026 | 157 | +4 | 27.98M | $15.17B | +8 | −5 |
| Q1 2026 | 157 | -1 | 29.64M | $17.54B | +5 | −7 |
| Q4 2025 | 157 | +1 | 32.29M | $15.72B | +2 | n/a |
| Q3 2025 | 21 | 0 | 20.11M | $8.43B | +1 | −2 |
| Q2 2025 | 19 | 0 | 20.17M | $5.79B | n/a | n/a |
| Q1 2025 | 16 | +1 | 10.14M | $3.12B | +1 | n/a |
| Q4 2024 | 15 | 0 | 10.52M | $3.71B | +1 | −1 |
| Q3 2024 | 14 | 0 | 8.99M | $3.22B | n/a | n/a |
| Q2 2024 | 14 | n/a | 8.17M | $2.60B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 2.23M | +1.4% | $687.66M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Renaissance Technologies ✦ | 2.11M | +0.8% | $649.52M | 1.0% | ▲ Add | 4 | SEC ↗ |
| 3 | Wellington Management ✦ | 2.03M | -17.8% | $624.68M | 0.1% | ▼ Trim | 4 | SEC ↗ ×9 |
| 4 | Geode Capital Management ✦ (passive) | 1.22M | +7.5% | $377.24M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | AQR Capital Management ✦ | 908.45K | -6.9% | $273.31M | 0.3% | ▼ Trim | 4 | SEC ↗ ×4 |
| 6 | Norges Bank ✦ (passive) | 466.35K | +8.4% | $143.76M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Arrowstreet Capital ✦ | 398.23K | -26.6% | $122.76M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 8 | Marshall Wace ✦ | 213.00K | New | $65.66M | 0.1% | New | 1 | SEC ↗ ×3 |
| 9 | Bridgewater Associates ✦ | 193.78K | +79.9% | $59.74M | 0.3% | ▲ Add | 4 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 189.73K | -52.3% | $58.49M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 11 | Gotham Asset Management ✦ | 89.34K | +46.0% | $27.54M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 36.18K | +77.9% | $11.15M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 30.27K | -30.1% | $9.33M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 14 | Fisher Asset Management ✦ | 18.59K | +13.8% | $5.73M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | Millennium Management ✦ | 4.04K | -85.6% | $1.24M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 16 | Two Sigma Investments ✦ | 1.52K | -14.0% | $470,112 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $65.66M | 0.1% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 844 holders, 41.22M shares, $23.10B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 315 sh · $176,612
Officer, Director · 320 sh · $178,280
Officer, Director · 520 sh · $290,537
Officer, Director · 586 sh · $322,311
Officer, Director · 1.13K sh · $624,870
Officer, Director · 1.56K sh · $860,883
Officer, Director · 1.26K sh · $697,996
Officer, Director · 575 sh · $314,977
Officer, Director · 948 sh · $520,400
Officer, Director · 464 sh · $261,130
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology